NOVARTIS (CACZ885M2301)

A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent   cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP.